CN1425425A - Medicine for preventing and curing osteoporosis and its preparing method - Google Patents
Medicine for preventing and curing osteoporosis and its preparing method Download PDFInfo
- Publication number
- CN1425425A CN1425425A CN 02154159 CN02154159A CN1425425A CN 1425425 A CN1425425 A CN 1425425A CN 02154159 CN02154159 CN 02154159 CN 02154159 A CN02154159 A CN 02154159A CN 1425425 A CN1425425 A CN 1425425A
- Authority
- CN
- China
- Prior art keywords
- medicine
- ethanol
- preparation
- drying
- kilogram
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The medicine for preventing and treating osteoporosis is prepared with the natural plants drynaria rhizome, desert cistanche, malaytea scurfpea fruit, epimedium, American ginseng, etc. and through drying, crushing, decoction and solvent extraction, mixing, disinfection and other steps of prepare medicine powder or table. The said preparation process can maintain the biological activity of the medicine components, and the medicine can raise the sexual hormone level of the body, stimulate the osteoplast to secret collagenase, release grorth factor and cell factor, raise the activity of the osteoplast to promote the production of bone matrix, speed the bone formation process, inhibit the dynamic balance of osteoclast and thus prevent and treating osteoporosis radically.
Description
Technical field
The present invention relates to the medicine of a kind of prevention, treatment osteoporosis, is the new drug of feedstock production with plant amedica (Chinese medicine) specifically.
The invention still further relates to the preparation method of this medicine.
Background technology
Osteoporosis (OPS) is a common ailment of middle-aged and old, is a kind of chronic disease that relates to many people and follow the continuous progress in a lot of years of people, because of sickness rate, disability rate and the mortality rate of its fracture that causes increases day by day.Because its high disability rate, mortality rate, the body misery of bringing to the mankind that causes of fracturing of being not only descends quality of life.And medical expenses that need be huge.At present, the whole world has 200,000,000 to go into to suffer from osteoporosis (OPS), and its sickness rate has leapt to the 7th of the various commonly encountered diseases in the world.In the U.S., Europe and Japan 7,500 ten thousand osteoporosis patients are arranged approximately according to statistics.According to the data of China 13 crowd of provinces and cities Investigation of bone mineral density results and nineteen ninety census, the number of patients 6000--8000 ten thousand of total osteoporosis occupies the first in the world, the ratio of men and women's prevalence 1.2: 3, and increase progressively with about 11% every year as radix.Therefore, osteoporosis has become a big health problem of global concern.
The direct medical cost that is used for osteoporotic fracture according to the measuring and calculating nineteen ninety-five U.S. reaches 13,800,000,000 US dollars, because the increase year by year of quantity takes place fracture.This respect spending also will further increase, and 1,700,000 routine Hip Fractures take place altogether in the whole world nineteen ninety according to statistics, because the size of population increases and the population forecast ILS, this NUMERICAL PREDICTION can be above 6,000,000 to the year two thousand fifty.America NI H estimates 5,200,000 routine hip vertebra and forearm fracture will take place, 45,000,000,000 US dollars of direct medical cost among the pink toes of the U.S. more than 45 years old in following 10 years.Have research to think that Chinese old people's Hip Fracture incidence rate also just increases with the ratio in every year 10%, the expense of calculating osteoporotic fracture in this ratio can increase undoubtedly greatly.
Carry out definition according to the osteoporosis of World Health Organization (WHO) and should carry out prevention of osteoporosis and treatment for the patient that low bone amount, osteoporosis or bone conversion increase.
The definition of osteoporosis is clearly put forward in nineteen ninety the 3rd world osteoporosis research association holding of Denmark, and the 4th world's osteoporosis seminar holding in 1993 Hong Kong obtains, and countries in the world generally acknowledge, that is: osteoporosis is to reduce with the bone amount, the microstructure degeneration of bone is a feature, cause bone fragility to increase, so that a kind of whole body skeletal diseases that is easy to fracture.Studies show that: the basic reason that osteoporosis takes place is a decrease in estrogen.
At present, drugs therapy of osteoporosis method and main developing direction are:
1, estrogen and analog thereof, 2, Calcium Metabolism Regulation hormone such as calcitonin etc., 3, bisphosphonates, 4, the other types medicine, comprise skeletal growth factor, fluoride, vitamin K and various calcium preparation.
The deficiency that exists is: calcium preparation just increases blood calcium, and not being increases bone formation, and the use of calcium preparation reduces fracture rates; Calcitonin does not have oral formulations and costs an arm and a leg; Diphosphonate, Yi Piao draw sweet smell etc. that tangible side effect of digestive tract etc. is arranged; Fluoride will reach effective therapeutic effect must take heavy dose (75mg) every day, and the treatment window is narrow, and the high dose administration also can weaken mineralization to the osteocyte toxigenicity, reduces the bone sedimentation rate and causes the osteomalacia to wait side effect.
Controversies in hormone replacement in the elderly (HRT) as first-selected therapeutic scheme, by reducing bone trabecular bone loss, obviously reduce total incidence rate of fracture, except that treatment osteoporosis (OPS), the alleviation menopause syndrome is arranged still, prevention ischemic heart desease and dementia are improved the genitourinary system functional defect, improve effects such as memory and cognitive competence, be used widely clinically, its effect at home and abroad all is sure (this has proved that also it is osteoporotic main cause that estrogen lacks).The deficiency that exists is: prolonged application HRT, risk factors such as the vaginal hemorrhage of appearance, breast tenderness, breast carcinoma, carcinoma of endometrium, migraine, deep venous thrombosis and pulmonary infarction are also more and more perplexing the doctor.
Therefore, the natural plants isoflavone is as selective estrogen receptor modulators, as the medicine of the prophylactic treatment osteoporosis of tool development potentiality and application prospect, has been that the our times various countries drop into the maximum research emphasis of funds.
It is reported, isoflavone only contains trace in bean (Semen sojae atricolor that Aisan is edible), dentation plant (as Herba Medicaginis), and this class plant is influenced by region, kind, harvest season etc., and its component difference is very big, promptly still can not extract and do medicinal application from the plant of finding now.
Summary of the invention
The object of the present invention is to provide a kind of whole raw material sources plant, have obvious raising men and women's sex hormone level and promote bone formation to increase and suppress the medicine of the prevention of bone resorption process, treatment osteoporosis.
Another object of the present invention provides manufacturing method for above mentioned medicine.
Solution of the present invention is based on the achievement of modern medicine to definition, the cause of disease, first-selected therapeutic scheme and the development trend research of osteoporosis, in conjunction with the Chinese nation's 5,000 years plant amedica (Chinese medicine) application experience, therefrom filter out the kidney invigorating bone strengthening, the body resistance strengthening and constitution consolidating, the homologous natural plant of medicated diet (Chinese medicine), by the theory of Chinese medical science prescription, the characteristics of the contained bioactive ingredients of each kind of plant of root a tree name (Chinese medicine), the application modern science and technology skims the cream off milk, it is played one's part to the full, improve the body sex hormone level.
Medicine of the present invention is made by following component: (consumption is a weight portion) Rhizoma Drynariae 5-25, Herba Cistanches 5-25, Fructus Psoraleae 5-25, Herba Epimedii 5-25, Radix Panacis Quinquefolii 0-20.
Formula optimization weight (part) ratio range of preparation medicine of the present invention is: Rhizoma Drynariae 5-15, Herba Cistanches 5-15, Fructus Psoraleae 5-15, Herba Epimedii 5-10, Radix Panacis Quinquefolii 5-10.
Medicine optimum weight of the present invention (part) proportioning is: Rhizoma Drynariae 15, Herba Cistanches 9.5, Fructus Psoraleae 9.5, Herba Epimedii 9.0, Radix Panacis Quinquefolii 5.0.
Above-mentioned each component is made medicine production method of the present invention is:
(1) get Rhizoma Drynariae, crushed after being dried to 60 order fineness, in Rhizoma Drynariae (kilogram): solvent (liter)=1: the 15-20 ratio adds solvent, soaks 20-24 hour in 8-10 ℃ of lucifuge, after-filtration removes slag, reclaim behind the solvent pale brown toner block;
(2) get Herba Cistanches, crushed after being dried to 60 order fineness, in Herba Cistanches (kilogram): water (liter)=1: the 8-10 ratio adds entry, boils the extraction secondary, and each 60 minutes, merge secondary filtrate, merging filtrate, drying with water bath get the brownish black colloid substance;
(3) get Fructus Psoraleae, crushed after being dried is 60 order fineness, and in Fructus Psoraleae (kilogram): ethanol (liter)=1: the 8-10 ratio adds ethanol, soaks 20-24 hour in 10-11 ℃ of lucifuge, and after-filtration removes slag, reclaim after the ethanol drying pale brown toner block;
(4) get Herba Epimedii, crushed after being dried to 60 order fineness, in Herba Epimedii (kilogram): ethanol (liter)=1: the 8-10 ratio adds ethanol, soaks 20-24 hour 8-10 ℃ of lucifuge, filter and remove residue reclaims ethanol, after the drying dark brown yellow powder block;
(5) get Radix Panacis Quinquefolii, dry post-treatment is crushed to 60 order fineness, and in Radix Panacis Quinquefolii (kilogram): water (liter)=1: the 10-12 ratio adds water, soaks 18-22 hour after-filtration at 10-25 ℃ and removes slag, and filtrate is at the 10-25 ℃ of loose powdery of following vacuum drying yellowly;
(6) medicated powder that above-mentioned (1), (2), (3), (4), (5) are made, cream component by described mixed after, under 60-80 ℃ of temperature, carried out the ripening sterilization treatment 90 minutes, make powder.
The ripening disinfecting action here is to adopt step type intensification ripening sterilization, insulation is 60 minutes when earlier temperature being risen to 60 ℃, be warming up to 80 ℃ then rapidly, be incubated and finish after 30 minutes, powder after the maturation process will be preserved under lucifuge, airtight, low temperature, and the time spent can be made into the preparation of all size as required.
Said solvent is methanol or 50%-60% ethanol in the preparation method of the present invention it (1).
Said ethanol is 70%-80% ethanol in preparation method of the present invention they (3), (4).
Said Herba Cistanches drying can be lyophilization in the preparation method of the present invention they (2).
Said Radix Panacis Quinquefolii drying can be lyophilization in the preparation method of the present invention they (5).
Important feature of the present invention is that constituent is the active component of natural plants (Chinese medicine) entirely, meets people's requirements of green environmental protection, wherein,
Rhizoma Drynariae (Drynaria baronii Diels) is a monarch drug.Contain 22(29)-Hopene, Fructus Citri grandis glycoside, D-glucose, L-rhamnose etc.Experimental results show that 1. application 45Ca2+ tracer method proof Rhizoma Drynariae have the Absorption of promotion bone to calcium, increasing blood calcium and serium inorganic phosphorus level, the calcification and the bone formation that help bone, 2. can significantly suppress the bone loss that cortisone acetate causes, prevent the osteoporosis rat that hormone causes, 3. Rhizoma Drynariae has effect for reducing blood fat in addition, analgesia, sedation.
Herba Cistanches (Cistanche desertico-la Y.C.Ma) is a ministerial drug.Contain the 6-methylindole, reach N-dimethylglycine methyl ester, carotene etc.Experimental results show that the contained chemical compound of 1. Herba Cistanches to suspention stress due to the study and the sexual disorder of male mice antagonism is arranged.2. the short luteal function of Herba Cistanches can strengthen hypothalamus--hypophysis--ovary improves hypophysis to the reaction to lutropin of the reaction of luteinizing hormone releasing hormone and ovary, and 3. Herba Cistanches can significantly prolong the life-span of fruit bat and improve immune effect.
Fructus Psoraleae (Psoralea Corylial) is a ministerial drug.Contain coumarin, neobavaisoflavone, chalcone, Corylifolinin etc.Experimental results show that: 1. Fructus Psoraleae can make the female Mus vagina keratinization of grow up normal and removal ovary increase.2. the female Mus to removal ovary can cause emotionally variation.Its uterus weight is obviously increased, stronger estrogen-like effects is arranged.3. the Corylifolinin of low concentration has tangible expansion artery effect.
Herba Epimedii (Epimedium Saqittatum Maxim) is a ministerial drug.Contain the epimedium flavone glycoside, icarisid, different an ancient wine vessel made of horn skin element, rhamnoside, hyperin, polysaccharide etc.Experimental results show that 1. Herba Epimedii can strengthen secretion functions such as hypothalamic pituitary gonadal axis and adrenal cortex axle, 2. can obviously increase normal rat antepituitary, ovary uterus weight, 3. Herba Epimedii has the growth of promotion effect to Embryo Gallus domesticus femur in vitro, and can promote protein synthesis.
Radix Panacis Quinquefolii: (Xiyangshen) be adjuvant drug.Contain 17 kinds of ginsenosides, contain multiple volatile ingredients such as capryl alcohol caproic acid-farnesene, and polysaccharide, pectin, 16 kinds are with upper amino acid and various trace elements.(the Radix Panacis Quinquefolii sweet in the mouth, little hardship and cold in nature, the function boosting qi and nourishing yin, the born fluid that relieves inflammation or internal heat is specially adapted to person in middle and old age's popularity deficiency of YIN and the card of fire is arranged.So Zhang Xichun cloud: " Radix Panacis Quinquefolii is cool in nature and mend, and all desires are not subjected to the temperature compensation person of the Radix Ginseng with Radix Ginseng, all can be for it.) modern times experiment showed, that 1. Radix Panacis Quinquefoliis have sedation to the central nervous system.2. anti-hypoxia and antifatigue effect are arranged.3. improve the effect of cardiovascular system.
Compared with prior art, the present invention has following advantage:
(1) to select the homologous natural plants of medicated diet (Chinese medicine) for use be raw material in the present invention, and each component meets the pharmaceutical control law regulation, has no side effect.
(2) medicament sources of the present invention is abundant, low price, and production process is environment friendly and pollution-free, the biological activity height.
(3) decoction process that medicine of the present invention need not Chinese medicine, taking convenience.
(4) medicine of the present invention all has remarkable result to men and women's property osteoporosis, and does not have side effect such as womanlike, sexual disorder.
(5) medicine of the present invention also has obvious curative effects to cardiovascular and cerebrovascular disease.
(6) the whole raw material sources plants of medicine of the present invention, have obvious raising men and women's sex hormone level and promote that bone formation increases, prevention ischemic heart desease and dull-wittedly alleviate menopause syndrome, improve the genitourinary system function, and do not have complication such as breast carcinoma, carcinoma of endometrium, migraine, deep venous thrombosis, male's secondary sexual characteristics go down.
(7) medicine all the components of the present invention all extracts from natural plants (Chinese medicine).Preparation method of the present invention makes the effective ingredient of medicine of the present invention keep higher biological activity, can obviously improve the body sex hormone level, stimulating osteoblast secretion collagenase, discharge somatomedin and cytokine, strengthen the osteoblastic active generation that promotes bone matrix, the accelerated bone forming process suppresses the dynamic equilibrium between the osteoclast simultaneously, fundamentally prevents, treats osteoporosis.
Have most the similar products daidzein of DEVELOPMENT PROSPECT and medicine of the present invention to do a pair of such as following on the relative effectivenes of estrogen-like effects with the first-selected curative estradiol of internationally recognized osteoporosis at most research at present both at home and abroad: with estradiol effectiveness is 100, then daidzein is 0.013, and medicine of the present invention is 55.The biopotency of medicine of the present invention is more than 4000 times of daidzein.
For show medicine of the present invention to the osteoporosis main diseases because of the therapeutical effect that---gonadal hormone reduces, make medicine of the present invention through HSPH of the Central China University of Science and Technology---strong ossein (medicine transient name) is to the experiment of mice sex hormone level influence, and the result is as follows.
Medicine of the present invention is to the regulating action of mice estrogen level:
Laboratory animal is kunming mice, and is female, 18 day age.Female body weight average 13 ± 1g.Female mice divides in groups at random by body weight, i.e. negative control group (normal saline group), experimental group (medicine of the present invention gives by 5g/Kgbw dosage), positive controls (diethylstilbestrol).Diethylstilbestrol dosage is 0.15mg/kgbw.
The nursing of animal adaptability after 3 days, by the body weight random packet, is freely drunk water feed.Irritate the stomach except that the normal saline group gives the equivalent normal saline, all the other each groups by every day 0.3mg/Kg gavage diethylstilbestrol, successive administration 3 days.Since the 4th day, each treated animal all gave by setting dosage, positive group by every day 0.15mg/Kg give diethylstilbestrol and irritate stomach.Irritating the stomach amount is 0.2ml/10gbw, continuous 15 days.
Fasting is 24 hours after the last administration, and extract eyeball and get blood, centrifugalize serum ,-70 ℃ of preservations are to be measured, separate female Mus uterus simultaneously and weigh.Estrogen (E in the serum
2) assay employing radioimmunology.
By table 1 as seen, each index of positive controls is compared with other groups, and significant difference (P＜0.05) is all arranged.Experimental group uterus weight, serum E
2The difference of comparing with negative control group has significance (P＜0.05).Table 1. medicine of the present invention is to female mouse uterine weight and the serum E of respectively organizing
2The influence of content is (the group uterus weight serum E of x ± s) relatively
2Content
(g) (pg/ml) negative control group 0.074 ± 0.010 1.102 ± 0.250 positive controls 0.139 ± 0.034 2.825 ± 0.240 experimental group 0.108 ± 0.036 1.570 ± 0.344
Experimental result shows: medicine of the present invention gives by 5g/Kgbw dosage, to female mice uterus weight and serum estrogen E2 level have a significant effect (P＜0.05).
Medicine of the present invention is to the regulating action of mice androgen level:
Kunming mice, male, 18 day age.Male body weight average 18 ± 1g.Male mice divides in groups at random by body weight, i.e. negative control group (normal saline group), experimental group (medicine of the present invention gives by 20g/kgbw dosage), positive controls (methyltestosterone).Methyltestosterone dosage is 10mg/kgbw.
The nursing of animal adaptability after 2 days, by the body weight random packet, is freely drunk water feed.Irritate the stomach except that the normal saline group gives the equivalent normal saline, each treated animal all gives by setting dosage, and positive component does not give hormone (methyltestosterone) and irritates stomach.Irritating the stomach amount is 0.2ml/10gbw, continuous 15 days.Estrogen in the serum (T) assay adopts radioimmunology.
By table 2 as seen, each index of positive controls is compared with other groups, and serum T content has significant difference (P＜0.05).Compare experimental group significance rising (P＜0.05) with negative control group.
Table 2: medicine of the present invention compares group serum T content to the male influence of respectively organizing mice serum T content
(ng/dl) negative control group 375.73 ± 218.40 positive controls 7350.42 ± 2780.80 experimental grouies 6890.08 ± 1950.32
Experimental result shows: medicine of the present invention has certain influence to male mice serum hormone T level, experimental group (20g/kgbw) has tangible effect to mice androgen level, compare with negative control group, significantly raise (P＜0.05), and compare no significant difference (P＞0.05) with positive group.
The specific embodiment
Embodiment 1.
Take by weighing raw material (kilogram) by following proportioning:
Rhizoma Drynariae 15 Herba Cistanches 9.5 Fructus Psoraleaes 9.5 Herba Epimedii 9.0 Radix Panacis Quinquefoliis 5
Above-mentioned each component is made medicine production method of the present invention is:
Get 15 parts of Rhizoma Drynariae, crushed after being dried is 60 order powder; In Rhizoma Drynariae (kilogram): 55% ethanol (liter)=ratio added ethanol in 1: 20, soaked 24 hours in 8-10 ℃ of lucifuge; After-filtration removes slag, and gets pale brown toner block behind the recovery ethanol.
After 9.5 parts of dryings of Herba Cistanches, be crushed to 60 order fineness; In Herba Cistanches (kilogram): water (liter)=ratio added entry in 1: 8, boiled the extraction secondary, and each 60 minutes, merge secondary filtrate, drying with water bath gets the brownish black colloid substance.
With 9.5 parts of drying and crushing of Fructus Psoraleae is 60 order powder; In Fructus Psoraleae (kilogram): 70% ethanol (liter)=ratio added ethanol in 1: 8, soaked 24 hours in 10-11 ℃ of lucifuge; Filter and remove residue gets pale brown toner piece thing after the recovery ethanol drying.
With 9.0 parts of Herba Epimedii, drying and crushing to 60 order fineness; In Herba Epimedii (kilogram): 78% ethanol (liter)=ratio added ethanol in 1: 10, soaked 24 hours 8-10 ℃ of lucifuge; Filter and remove residue reclaims ethanol, gets dark brown yellow powder block after the drying.
Get 5 parts of dryings of Radix Panacis Quinquefolii, it is 60 order fineness that post-treatment is pulverized; In Radix Panacis Quinquefolii (kilogram): water (liter)=ratio added entry in 1: 10, at 10-25 ℃, soaked 18 hours; After-filtration removes slag, and filtrate is at the 10-25 ℃ of loose powdery of following vacuum drying yellowly.
By after the described mixed, insulation is 60 minutes when earlier temperature being risen to 60 ℃, is warming up to 80 ℃ then rapidly, is incubated and finishes after 30 minutes with above-mentioned whole medicated powder, cream component.Powder after the maturation process will be preserved under lucifuge, airtight, low temperature.Time spent can be made into the preparation of all size as required.
Embodiment 2.
Take by weighing raw material (kilogram) by following proportioning:
Rhizoma Drynariae 25.0 Herba Cistanches 15 Fructus Psoraleaes 15.0 Herba Epimedii 10.0 Radix Panacis Quinquefoliis 8.0
Above-mentioned each component is made medicine production method of the present invention is:
Get 25 parts of Rhizoma Drynariae earlier, drying and crushing to 60 order powder.In Rhizoma Drynariae (kilogram): 50% ethanol (liter)=ratio added ethanol in 1: 20, soaked 24 hours in 8-10 ℃ of lucifuge, and after-filtration removes slag, reclaim behind the ethanol pale brown toner block.
After 15 parts of lyophilizations of Herba Cistanches, be crushed to 60 orders.In Herba Cistanches (kilogram): water (liter)=ratio added entry in 1: 10, boiled the extraction secondary, each 60 minutes, merged secondary filtrate.Drying with water bath gets the brownish black colloid substance.
With 15 parts of drying and crushing of Fructus Psoraleae is 60 orders, and in Fructus Psoraleae (kilogram): 70% ethanol (liter)=ratio added ethanol in 1: 10, soaked 24 hours in 10-11 ℃ of lucifuge, and filter and remove residue reclaims ethanol, dried pale brown toner piece thing.
With 10 parts of Herba Epimedii, crushed after being dried to 60 order, in Herba Epimedii (kilogram): 78% ethanol (liter)=ratio added ethanol in 1: 8, soaked 24 hours 8-10 ℃ of lucifuge, and filter and remove residue reclaims ethanol, dried dark brown yellow powder block.
Get 8 parts of Radix Panacis Quinquefoliis ,-15 ℃ of following lyophilizations, it is 60 order fineness that post-treatment is pulverized, and by Radix Panacis Quinquefolii (kilogram): water (liter)=ratio added entry in 1: 12, and 10-25 ℃ of immersion 20 hours, filtrate was at the 10-25 ℃ of loose powdery of following vacuum drying yellowly.
By after the described mixed, insulation is 60 minutes when earlier temperature being risen to 60 ℃, is warming up to 80 ℃ then rapidly, is incubated and finishes after 30 minutes with above-mentioned whole medicated powder cream components.Powder after the maturation process will be preserved under lucifuge, airtight, low temperature.Time spent can be made into the preparation of all size as required.
Embodiment 3.
Take by weighing raw material (kilogram) by following proportioning:
Rhizoma Drynariae 10.0 Herba Cistanches 6.0 Fructus Psoraleaes 6.0 Herba Epimedii 6.0 Radix Panacis Quinquefoliis 5.0
Above-mentioned each component is made medicine production method of the present invention is:
Get 10 parts of Rhizoma Drynariae earlier, 10 parts of microliths (0.1--1.0CM diameter) are put into cylinder type medicine roasting machine and are stirred to rotate and saw that Rhizoma Drynariae is heaved in about 20 minutes and color is sallow and get final product, take the dish out of the pot to sift out microlith and concoct Rhizoma Drynariae drying and crushing to 60 order powder afterwards.In Rhizoma Drynariae (kilogram): 55% (liter)=ratio added ethanol in 1: 15, soaked 22 hours in 8-10 ℃ of lucifuge, and after-filtration removes slag, reclaim behind the ethanol pale brown toner block.
After 6 parts of lyophilizations of Herba Cistanches, be crushed to 60 orders.In Herba Cistanches (kilogram): water (liter)=ratio added entry in 1: 8, and little fire decocted 45 minutes, after the filtration again in Herba Cistanches (kilogram): water (liter)=ratio added entry in 1: 8, repeated decoction once, merging secondary filtrate, drying with water bath gets the brownish black colloid substance.
With 6 parts of drying and crushing of Fructus Psoraleae is 60 orders, presses Fructus Psoraleae (kilogram): 70% ethanol (liter)=1: 8, and 10-11 ℃ of lucifuge soaked 20 hours, and filter and remove residue reclaims the dried pale brown toner piece thing of ethanol.
After 6 parts of Adeps caprae seu ovis of Herba Epimedii are concocted, drying and crushing to 60 order, by Herba Epimedii (kilogram): 78% ethanol (liters)=ratio added ethanol in 1: 10,8-10 ℃ of lucifuge immersion 20 hours, filter and remove residue, recovery ethanol gets dark brown yellow powder block after the drying.
Get 5 parts of Radix Panacis Quinquefoliis-15 ℃ of following lyophilizations, it is 60 order fineness that post-treatment is pulverized, and in Radix Panacis Quinquefolii (kilogram): water (liter)=ratio added entry in 1: 12, soaked 18 hours, and filtrate is at the 10-25 ℃ of loose powdery of following vacuum drying yellowly.
By after the described mixed, insulation is 60 minutes when earlier temperature being risen to 60 ℃, is warming up to 80 ℃ then rapidly, is incubated and finishes after 30 minutes with above-mentioned whole medicated powder cream components.Powder after the maturation process will be preserved under lucifuge, airtight, low temperature.Time spent can be made into the preparation of all size as required.
Claims (10)
1, a kind of prevention, treat osteoporotic medicine, it is characterized in that it is the medicament of being made by the following weight proportion raw material:
Rhizoma Drynariae 5-25, Herba Cistanches 5-25, Fructus Psoraleae 5-25, Herba Epimedii 5-25, Radix Panacis Quinquefolii 0-20.
The medicine of 2, prevention according to claim 1, treatment osteoporosis is characterized in that wherein the weight proportion of each raw material is:
Rhizoma Drynariae 5-15, Herba Cistanches 5-15, Fructus Psoraleae 5-15, Herba Epimedii 5-10, Radix Panacis Quinquefolii 5-10.
The medicine of 3, prevention according to claim 1, treatment osteoporosis is characterized in that wherein the weight proportion of each raw material is:
Rhizoma Drynariae 15, Herba Cistanches 9.5, Fructus Psoraleae 9.5, Herba Epimedii 9.0, Radix Panacis Quinquefolii 5.0.
4, according to the medicine of claim 1,2 or 3 described preventions, treatment osteoporosis, it is characterized in that being that said medicament is a said dosage form on any pharmaceutics.
5, prevention according to claim 4, treatment osteoporosis agents is characterized in that said medicament is powder or piece agent.
The preparation method of 6, prevention according to claim 5, treatment osteoporosis agents is characterized in that:
(1) get Rhizoma Drynariae, crushed after being dried to 60 order fineness, in Rhizoma Drynariae (kilogram): solvent (liter)=1: the 15-20 ratio adds solvent, soaks 20-24 hour in 8-10 ℃ of lucifuge, after-filtration removes slag, reclaim behind the solvent pale brown toner block;
(2) get Herba Cistanches, crushed after being dried to 60 order fineness, in Herba Cistanches (kilogram): water (liter)=1: the 8-10 ratio adds water, boils the extraction secondary, and each 60 minutes, merge secondary filtrate, drying with water bath gets the brownish black colloid substance;
(3) get Fructus Psoraleae, crushed after being dried is 60 order fineness, and in Fructus Psoraleae (kilogram): ethanol (liter)=1: the 8-10 ratio adds ethanol, soaks 20-24 hour in 10-11 ℃ of lucifuge, and after-filtration removes slag, reclaim after the ethanol drying pale brown toner block;
(4) get Herba Epimedii, crushed after being dried to 60 order fineness, in Herba Epimedii (kilogram): ethanol (liter)=1: the 8-10 ratio adds ethanol, soaks 20-24 hour in 8-10 ℃ of lucifuge, filter and remove residue reclaims ethanol, after the drying dark brown yellow powder block;
(5) get Radix Panacis Quinquefolii, dry post-treatment is crushed to 60 order fineness, and in Radix Panacis Quinquefolii (kilogram): water (liter)=1: the 10-12 ratio adds water, at 10-25 ℃, soaks 18-22 hour after-filtration and removes slag, and filtrate is at the 10-25 ℃ of loose powdery of following vacuum drying yellowly;
(6) with the medicated powder of preparation in above-mentioned (1), (2), (3), (4), (5), cream component by after the described mixed, under 60-80 ℃ of temperature, carried out the ripening sterilization treatment 90 minutes, make powder.
The preparation method of the medicine of 7, prevention according to claim 6, treatment osteoporosis is characterized in that said solvent is methanol or 50%-60% ethanol in the preparation method it (1).
The preparation method of the medicine of 8, prevention according to claim 6, treatment osteoporosis is characterized in that said ethanol is 70%-80% ethanol in preparation method they (3), (4).
The preparation method of the medicine of 9, prevention according to claim 6, treatment osteoporosis is characterized in that said Herba Cistanches drying can be lyophilization in the preparation method they (2); Said Radix Panacis Quinquefolii drying can be lyophilization in the preparation method they (5).
The preparation method of the medicine of 10, prevention according to claim 6, treatment osteoporosis, it is characterized in that the ripening disinfecting action is to adopt step type intensification ripening sterilization, insulation is 60 minutes when earlier temperature being risen to 60 ℃, be warming up to 80 ℃ then rapidly, be incubated and finish after 30 minutes, powder after the maturation process will be preserved under lucifuge, airtight, low temperature, and the time spent can be made into the preparation of all size as required.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021541590A CN1330325C (en) | 2002-12-27 | 2002-12-27 | Medicine for preventing and curing osteoporosis and its preparing method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021541590A CN1330325C (en) | 2002-12-27 | 2002-12-27 | Medicine for preventing and curing osteoporosis and its preparing method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1425425A true CN1425425A (en) | 2003-06-25 |
| CN1330325C CN1330325C (en) | 2007-08-08 |
Family
ID=4752444
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB021541590A Expired - Fee Related CN1330325C (en) | 2002-12-27 | 2002-12-27 | Medicine for preventing and curing osteoporosis and its preparing method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1330325C (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103599239A (en) * | 2013-11-01 | 2014-02-26 | 于明儒 | Traditional Chinese medicine ointment for treating osteoporosis |
| CN106213486A (en) * | 2016-07-20 | 2016-12-14 | 柳州名品科技有限公司 | A kind of improve the health food that sclerotin is loose |
| CN110146600A (en) * | 2018-02-13 | 2019-08-20 | 国药集团同济堂（贵州）制药有限公司 | The preparation method and its detection method of psoralea corylifolia standard decoction |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1060345C (en) * | 1993-07-24 | 2001-01-10 | 高风兰 | Shengliyangshengye-nourishing liquid for building up strength |
| CN1061884C (en) * | 1997-09-09 | 2001-02-14 | 刘强 | Chinese medicine for ischemic necrosis of thighbone head |
-
2002
- 2002-12-27 CN CNB021541590A patent/CN1330325C/en not_active Expired - Fee Related
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103599239A (en) * | 2013-11-01 | 2014-02-26 | 于明儒 | Traditional Chinese medicine ointment for treating osteoporosis |
| CN106213486A (en) * | 2016-07-20 | 2016-12-14 | 柳州名品科技有限公司 | A kind of improve the health food that sclerotin is loose |
| CN110146600A (en) * | 2018-02-13 | 2019-08-20 | 国药集团同济堂（贵州）制药有限公司 | The preparation method and its detection method of psoralea corylifolia standard decoction |
| CN110146600B (en) * | 2018-02-13 | 2022-04-26 | 国药集团同济堂（贵州）制药有限公司 | Preparation method and detection method of fructus psoraleae standard decoction |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1330325C (en) | 2007-08-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101513437B (en) | Antifatigue Chinese pharmaceutical composition and preparation method thereof | |
| CN101856114B (en) | Health food with bone intensity enhancing function and preparation method thereof | |
| CN1243735A (en) | Skin regrowing powder and its preparing process | |
| CN1958039A (en) | Preparation of Chinese traditional medicine for treating cardiovascular disease, and cerebrovascular disease | |
| CN1824155A (en) | Medicine used for kidney supplementing and its preparation method | |
| CN1931353A (en) | Curcuma extract and its prepn process, medicine composition and use | |
| CN1806840A (en) | Chinese medicinal compound preparation and its preparing process | |
| CN1907316A (en) | Orthopaedics disease treating and preventing medicinal composition | |
| CN1742775A (en) | Medicine composition for preventing and treating orthopedic diseases | |
| CN1899590A (en) | Gynecological Chinese patented medicine for relieving depressed liver and clearing heat, strengthening spleen and nourishing blood and its preparing method | |
| CN102626463A (en) | Natural medicine compound for increasing bone mineral density and preventing and treating osteoporosis | |
| CN101028325A (en) | Medicinal composition containing sailonggu, and its preparation and quality control | |
| CN1225273C (en) | Nutritious health care food and preparation prlcess thereof | |
| CN1330325C (en) | Medicine for preventing and curing osteoporosis and its preparing method | |
| CN1232279C (en) | Antilipemic Chinese medicine | |
| CN102114070B (en) | Compound traditional Chinese medicine for treating osteoporosis and preparation method thereof | |
| CN1857561A (en) | Osteoporosis treating medicine and its preparing method | |
| CN104257762A (en) | Drug combination and purpose for preventing and curing osteoporosis | |
| CN107812039A (en) | A kind of beautiful millettia root Chinese medicine composition with function of reinforcing the kidney to strengthen the bone and preparation method thereof | |
| CN111388639B (en) | Phenylethanoid glycoside and isoflavone extract for relieving menopausal syndrome and application thereof | |
| CN1105557A (en) | Method for preparation of weight-loosing medicine and its products | |
| CN1230191C (en) | Health care combination of propolis for reducing blood sugar and fat as well as method for mfg. its capsule | |
| CN1183936C (en) | Medicine for treating hypertension and method for preparing medicinal tea thereof | |
| CN104162090B (en) | Pharmaceutical composition and preparation method thereof | |
| CN1229131C (en) | Medicine for treating kidney yang and preparing method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |